Chamoto Kenji, Yaguchi Tomonori, Tajima Masaki, Honjo Tasuku
Division of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Division of Integrated High-Order Regulatory Systems, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nat Rev Immunol. 2023 Oct;23(10):682-695. doi: 10.1038/s41577-023-00867-9. Epub 2023 Apr 25.
PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding overactivation-induced cell death and autoimmunity, whereas its inhibition unleashes anticancer immunity. Here, we outline the journey from the discovery of PD1 to its role as a breakthrough target in cancer immunotherapy. We describe its regulation and function and examine how a mechanistic understanding of PD1 signalling suggests a central function in setting the T cell activation threshold, thereby controlling T cell proliferation, differentiation, exhaustion and metabolic status. This threshold theory, in combination with new insights into T cell metabolism and a better understanding of immune cell modulation by the microbiota, can provide guidance for the development of efficient combination therapies. Moreover, we discuss the mechanisms underlying immune-related adverse events after PD1-targeted therapy and their possible treatment.
程序性死亡蛋白1(PD1)最初于1992年被发现,是一种与T细胞激活诱导的细胞死亡相关的分子。在过去30年里,人们发现PD1在避免过度激活诱导的细胞死亡和自身免疫方面起着关键作用,而对其抑制则可释放抗癌免疫。在此,我们概述了从PD1的发现到其作为癌症免疫治疗突破性靶点的历程。我们描述了其调节和功能,并探讨了对PD1信号传导的机制性理解如何表明其在设定T细胞激活阈值方面的核心功能,从而控制T细胞的增殖、分化、耗竭和代谢状态。这种阈值理论,结合对T细胞代谢的新见解以及对微生物群对免疫细胞调节的更好理解,可为开发高效联合疗法提供指导。此外,我们讨论了PD1靶向治疗后免疫相关不良事件的潜在机制及其可能的治疗方法。